DE60143354D1 - Nuklearfaktor kb induzierender faktor - Google Patents
Nuklearfaktor kb induzierender faktorInfo
- Publication number
- DE60143354D1 DE60143354D1 DE60143354T DE60143354T DE60143354D1 DE 60143354 D1 DE60143354 D1 DE 60143354D1 DE 60143354 T DE60143354 T DE 60143354T DE 60143354 T DE60143354 T DE 60143354T DE 60143354 D1 DE60143354 D1 DE 60143354D1
- Authority
- DE
- Germany
- Prior art keywords
- nfif
- polypeptides
- methods
- factor
- nfkb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 5
- 230000006698 induction Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- -1 NFIF-14b and NFIF-7a Proteins 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19390500P | 2000-03-31 | 2000-03-31 | |
| GBGB0018307.9A GB0018307D0 (en) | 2000-07-26 | 2000-07-26 | Polypeptides |
| PCT/US2001/010719 WO2001074900A2 (en) | 2000-03-31 | 2001-04-02 | Nuclear factor kb inducing factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60143354D1 true DE60143354D1 (de) | 2010-12-09 |
Family
ID=26244722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60143354T Expired - Lifetime DE60143354D1 (de) | 2000-03-31 | 2001-04-02 | Nuklearfaktor kb induzierender faktor |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1290023B1 (enExample) |
| JP (1) | JP4750999B2 (enExample) |
| KR (1) | KR100811571B1 (enExample) |
| AT (1) | ATE486089T1 (enExample) |
| AU (1) | AU4793101A (enExample) |
| CA (1) | CA2404688C (enExample) |
| DE (1) | DE60143354D1 (enExample) |
| DK (1) | DK1290023T3 (enExample) |
| IL (3) | IL151987A0 (enExample) |
| MX (1) | MXPA02009481A (enExample) |
| NO (1) | NO331972B1 (enExample) |
| NZ (1) | NZ521786A (enExample) |
| PT (1) | PT1290023E (enExample) |
| WO (1) | WO2001074900A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117534753B (zh) * | 2023-12-07 | 2024-05-10 | 北京博奥森生物技术有限公司 | 一种诱导高性能NF-κB多克隆抗体多肽及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3486053T3 (de) | 1983-10-20 | 2004-01-08 | The Research Foundation Of State University Of New York | Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS. |
| FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| WO1993008845A1 (en) | 1991-11-08 | 1993-05-13 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| EP0651805B1 (en) | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method of intracellular binding of target molecules |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| WO1997037020A1 (en) * | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| US6235512B1 (en) * | 1997-07-01 | 2001-05-22 | Tularik Inc. | IKK-α proteins, nucleic acids and methods |
| US6132964A (en) * | 1998-02-06 | 2000-10-17 | Incyte Pharmaceuticals, Inc. | Hydrolase enzymes |
| AU4187499A (en) * | 1998-05-14 | 1999-11-29 | Chiron Corporation | Human genes and gene expression products v |
| GB9814036D0 (en) * | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
| US6077672A (en) * | 1998-08-28 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of TRADD expression |
| CN1302897A (zh) * | 1999-10-28 | 2001-07-11 | 上海博容基因开发有限公司 | 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸 |
| CA2402563A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1358347A2 (en) * | 2000-04-05 | 2003-11-05 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| EP1358349A2 (en) * | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
-
2001
- 2001-04-02 JP JP2001572589A patent/JP4750999B2/ja not_active Expired - Fee Related
- 2001-04-02 DK DK01920925.3T patent/DK1290023T3/da active
- 2001-04-02 EP EP01920925A patent/EP1290023B1/en not_active Expired - Lifetime
- 2001-04-02 AT AT01920925T patent/ATE486089T1/de active
- 2001-04-02 PT PT01920925T patent/PT1290023E/pt unknown
- 2001-04-02 MX MXPA02009481A patent/MXPA02009481A/es active IP Right Grant
- 2001-04-02 IL IL15198701A patent/IL151987A0/xx unknown
- 2001-04-02 AU AU4793101A patent/AU4793101A/xx not_active Withdrawn
- 2001-04-02 WO PCT/US2001/010719 patent/WO2001074900A2/en not_active Ceased
- 2001-04-02 CA CA2404688A patent/CA2404688C/en not_active Expired - Fee Related
- 2001-04-02 DE DE60143354T patent/DE60143354D1/de not_active Expired - Lifetime
- 2001-04-02 KR KR1020027013083A patent/KR100811571B1/ko not_active Expired - Fee Related
- 2001-04-02 NZ NZ521786A patent/NZ521786A/en not_active IP Right Cessation
-
2002
- 2002-09-27 NO NO20024656A patent/NO331972B1/no not_active IP Right Cessation
- 2002-09-29 IL IL151987A patent/IL151987A/en not_active IP Right Cessation
-
2009
- 2009-04-16 IL IL198132A patent/IL198132A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL151987A (en) | 2010-12-30 |
| AU4793101A (en) | 2001-10-15 |
| HK1053312A1 (en) | 2003-10-17 |
| DK1290023T3 (da) | 2011-02-14 |
| EP1290023A2 (en) | 2003-03-12 |
| KR100811571B1 (ko) | 2008-03-10 |
| IL151987A0 (en) | 2003-04-10 |
| NO331972B1 (no) | 2012-05-14 |
| JP2003529360A (ja) | 2003-10-07 |
| KR20020087459A (ko) | 2002-11-22 |
| WO2001074900A9 (en) | 2003-03-06 |
| CA2404688C (en) | 2012-07-31 |
| CA2404688A1 (en) | 2001-10-11 |
| JP4750999B2 (ja) | 2011-08-17 |
| WO2001074900A3 (en) | 2002-05-02 |
| WO2001074900A2 (en) | 2001-10-11 |
| PT1290023E (pt) | 2011-01-05 |
| NO20024656D0 (no) | 2002-09-27 |
| IL198132A0 (en) | 2011-08-01 |
| EP1290023B1 (en) | 2010-10-27 |
| MXPA02009481A (es) | 2004-05-14 |
| NZ521786A (en) | 2004-07-30 |
| NO20024656L (no) | 2002-11-28 |
| ATE486089T1 (de) | 2010-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
| SE9800836D0 (sv) | New Compounds | |
| CY1120241T1 (el) | Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου | |
| EP1446012A4 (en) | Bacteriolytic combination therapy for the treatment of tumors | |
| NO20033862D0 (no) | Fremgangsmåter for forebyggelse eller behandling av inflammatoriske eller autoimmune sykdommer ved administrering av integrin-alfa-beta3-antagonister | |
| ATE232396T1 (de) | Oxydiertes thymosin beta 4 | |
| DE60221569D1 (de) | Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen | |
| FR2849781B1 (fr) | Sonde de therapie | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| ATE512221T1 (de) | Durch oligonukleotide vermittelte spezifische zytokin-induktion und in-vivo infektionsschutz | |
| CL2004001174A1 (es) | Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia | |
| ITMI20010684A0 (it) | Dispositivo e procedimento di controllo della entita' del grasso intra-addominale | |
| EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
| PT1326853E (pt) | Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7 | |
| CY1110114T1 (el) | Προσδετης αλφα-2-δελτα για την αγωγη των συμπτωματων του κατωτερου ουροποιητικου συστηματος | |
| HUP9900819A1 (hu) | Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában | |
| FR2834889B1 (fr) | Forme pharmaceutique solide orodispersible | |
| ITNA20000036A0 (it) | Nuovi approcci terapeutici per il trattamento della forfora. | |
| DE60143354D1 (de) | Nuklearfaktor kb induzierender faktor | |
| ATE406438T1 (de) | Menschliches homolog aus der familie der metalloproteasen | |
| EE200300328A (et) | IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks | |
| CY1106363T1 (el) | Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων | |
| DE60114597D1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| BR0109721A (pt) | Fator de indução do fator kb nuclear | |
| DE50208267D1 (de) | Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit |